ArticleJournal of veterinary research2025
Yolkin restores cellular immune response and content of T and B cells in lymphoid organs of cyclophosphamide-immunocompromised mice.
Article in Journal of veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Yolkin tempers inflammatory mediator release and liver pathology in experimental endotoxemia in mice.Histology and histopathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Yolkin is an egg yolk-derived protein with well-established immunoregulatory activities. In this study its potential restorative properties in cyclophosphamide (CP)-immunocompromised mice were evaluated. Material and Methods: Mice were treated with a sublethal dose of CP, followed by an access to yolkin contained in drinking water. The mice were immunised with oxazolone (OXA) for contact sensitivity (CS) and with ovalbumin (OVA) for the antibody specific response after 15 or 26 days of treatment with yolkin, respectively. The lymphoid organs were isolated for determination of immune cell numbers and their phenotypes. Results: A significant suppression of CS following CP treatment and a restoration of this response by yolkin were found. However, no effects of CP and yolkin on the antibody response were registered. In the case of CS a significant loss of T cell numbers in splenocytes was noted. The restoration of CS correlated with reversal of CD3+, CD4+ and CD8+ T cell loss to 88%, 89% and 76.6% of the values observed in the control mice. A significant depletion of the B cells, and all bone marrow cells after CP treatment, was completely restored after 26 day treatment with yolkin. Conclusion: The presented results add new information to the already described immunoregulatory properties of the protein and indicate a potential of oral yolkin in restoration of cellular immune response in immunocompromised individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.